Samit Hirawat Purchases 1,830 Shares of Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb (NYSE:BMY) EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $0.51 during trading hours on Tuesday, hitting $55.96. The stock had a trading volume of 9,271,368 shares, compared to its average volume of 14,442,866. The stock’s fifty day simple moving average is $51.56 and its 200 day simple moving average is $46.66. The firm has a market capitalization of $113.50 billion, a price-to-earnings ratio of -15.59, a PEG ratio of 13.14 and a beta of 0.44. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $56.28.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the business earned $2.00 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. Sell-side analysts anticipate that Bristol-Myers Squibb will post 0.83 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.29%. Bristol-Myers Squibb’s dividend payout ratio is presently -66.85%.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. BMO Capital Markets increased their price target on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the stock a “market perform” rating in a research report on Friday. Citigroup lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $75.00 to $55.00 in a research report on Friday, October 25th. Sanford C. Bernstein began coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target on the stock. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Institutional Trading of Bristol-Myers Squibb

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Aptus Capital Advisors LLC boosted its stake in Bristol-Myers Squibb by 25.5% during the third quarter. Aptus Capital Advisors LLC now owns 21,738 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 4,421 shares in the last quarter. Commonwealth Retirement Investments LLC grew its stake in shares of Bristol-Myers Squibb by 8.4% in the 3rd quarter. Commonwealth Retirement Investments LLC now owns 45,487 shares of the biopharmaceutical company’s stock worth $2,354,000 after purchasing an additional 3,541 shares during the last quarter. American Assets Inc. bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $621,000. Savvy Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $250,000. Finally, Ashton Thomas Private Wealth LLC grew its position in Bristol-Myers Squibb by 57.3% in the third quarter. Ashton Thomas Private Wealth LLC now owns 50,480 shares of the biopharmaceutical company’s stock worth $2,612,000 after buying an additional 18,383 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.